{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-25-000004","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.039437+00:00","generated_at":"2026-05-28T03:45:48.766966+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"GeneDx reports prelim FY2024 revenue ≥$299M (+54% YoY), above prior guidance","bullets":["Preliminary FY2024 revenue at least $299M (+54% YoY), above prior guidance of $284-290M.","Q4 2024 revenue at least $92M (+59% YoY, +20% sequential); exome/genome rev $75.8M (+93% YoY).","Adjusted gross margin ≥64% FY (guidance ≥62%) and ≥68% in Q4 (up from 64% Q3).","Q4 exome/genome volume 20,676 (+32% YoY, +7% seq); expects second consecutive adjusted net income quarter and first positive operating cash flow.","Includes $6.8M discrete benefit from multi-year appeal recovery from a single payer."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-25-000004","json":"https://secwatch.observer/filing/0001818331-25-000004.json","markdown":"https://secwatch.observer/filing/0001818331-25-000004.md","text":"https://secwatch.observer/filing/0001818331-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833125000004/0001818331-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833125000004/wgs-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:45:48.766966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}